ARK Investment Management LLC Has $43.50 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

ARK Investment Management LLC raised its position in Moderna, Inc. (NASDAQ:MRNA) by 68.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 437,403 shares of the company’s stock after acquiring an additional 177,565 shares during the period. ARK Investment Management LLC’s holdings in Moderna were worth $43,500,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in MRNA. RB Capital Management LLC raised its holdings in Moderna by 7.5% in the 1st quarter. RB Capital Management LLC now owns 2,267 shares of the company’s stock valued at $391,000 after acquiring an additional 158 shares in the last quarter. Synovus Financial Corp raised its holdings in shares of Moderna by 8.0% in the 1st quarter. Synovus Financial Corp now owns 4,049 shares of the company’s stock worth $704,000 after buying an additional 300 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Moderna by 5.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 987,478 shares of the company’s stock worth $170,121,000 after buying an additional 47,755 shares in the last quarter. Blair William & Co. IL raised its holdings in shares of Moderna by 12.4% in the 1st quarter. Blair William & Co. IL now owns 15,611 shares of the company’s stock worth $2,689,000 after buying an additional 1,724 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Moderna by 41.4% in the 1st quarter. Sei Investments Co. now owns 58,160 shares of the company’s stock worth $10,019,000 after buying an additional 17,031 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on MRNA shares. Canaccord Genuity Group increased their target price on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a report on Friday, February 23rd. HSBC restated a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Royal Bank of Canada restated an “outperform” rating and set a $125.00 price target on shares of Moderna in a research report on Friday, February 23rd. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target on the stock in a research report on Tuesday, January 2nd. Finally, Canaccord Genuity Group began coverage on Moderna in a research report on Wednesday, November 29th. They set a “hold” rating and a $82.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $129.82.

Moderna Stock Performance

MRNA stock opened at $110.59 on Thursday. The business’s fifty day moving average is $98.79 and its 200-day moving average is $93.49. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. The company has a market cap of $42.34 billion, a P/E ratio of -8.91 and a beta of 1.60. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $163.24.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm’s revenue was down 44.9% compared to the same quarter last year. During the same quarter last year, the business posted $3.61 EPS. Equities research analysts forecast that Moderna, Inc. will post -7.48 EPS for the current year.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 544 shares of Moderna stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $99.05, for a total value of $53,883.20. Following the sale, the insider now owns 9,267 shares of the company’s stock, valued at approximately $917,896.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Shannon Thyme Klinger sold 544 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $99.05, for a total transaction of $53,883.20. Following the sale, the insider now owns 9,267 shares in the company, valued at $917,896.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James M. Mock sold 647 shares of the company’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares in the company, valued at approximately $406,651. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,021 shares of company stock valued at $5,211,442. 15.70% of the stock is owned by company insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.